Atrosab

**Atrosab** is a humanized IgG1 monoclonal antibody that selectively antagonizes **TNFR1** (tumor necrosis factor receptor superfamily member 1A), inhibiting TNF- and LTα-mediated pro-inflammatory signaling, apoptosis, NFκB activation, and cytokine release (e.g., IL-6, IL-8) without affecting TNFR2-mediated protective functions. Developed initially by Celonic AG, it features a mutated Fc region to minimize ADCC and CDC. Preclinical studies demonstrated efficacy in models of inflammatory diseases (e.g., rheumatoid arthritis, experimental autoimmune encephalomyelitis for multiple sclerosis, non-alcoholic steatohepatitis) and acute neurodegeneration (e.g., NMDA-induced excitotoxicity), though a phase 1 trial revealed dose-limiting side effects due to marginal agonistic activity from bivalent binding, leading to monovalent derivative Atrosimab.

Other names

atrosab-MSAnti-TNF-receptor-1 monoclonal antibodyAnti-TNF-receptor1 monoclonal antibodyAnti-TNF-receptor 1 monoclonal antibody